Table 3.
Characteristics of study participants with NAFLD (based on CAP ≥263) stratified by BMI
| Variables N = 155 |
BMI<25 kg/m2 N = 51 |
BMI≥25 kg/m2 N = 104 |
P-value |
|---|---|---|---|
| Age (Year) | 52.8 (9.5) | 50.8 (10.4) | 0.25 |
| Gender | 0.09 | ||
| Male | 39 (76.5%) | 66 (63.5%) | |
| Cisgender Female | 11 (21.6%) | 26 (25%) | |
| Transgender female | 1 (1.9%) | 12 (11.5%) | |
| Race | 0.22 | ||
| White | 34 (66.7%) | 60 (57.7%) | |
| Black | 11 (21.6%) | 36 (34.6%) | |
| Other | 6 (11.8%) | 8 (7.7%) | |
| Ethnicity | 0.19 | ||
| Hispanic or Latino | 21 (41.9%) | 29 (27.9%) | |
| Non-Hispanic | 30 (58.0%) | 74 (71.1%) | |
| Unknown | 0 | 1 (1%) | |
| Waist circumference (cm) | 96.6 (8.8) | 115.9 (11.4) | <0.01 |
| Diabetes Mellitus | 13 (25.5%) | 14 (13.7%) | 0.07 |
| ALT (U/L) | 43.0 (35.0) | 37.7 (34.8) | 0.38 |
| ALT >40 (U/L) | 19 (38%) | 28 (27.2%) | 0.17 |
| Abnormal ALT ( >30 U/L in men and >19 U/L in women) | 28 (56%) | 48 (52.2%) | 0.66 |
| AST (U/L) | 32.4 (19.8) | 28.2 (18.9) | 0.21 |
| AST >40 (U/L) | 12 (24%) | 14 (13.6%) | 0.11 |
| Platelets 109/L) | 239.1 (71.6) | 245.0 (62.0) | 0.60 |
| Triglycerides (mg/dL) | 178.6 (184.6) | 172.4 (94.4) | 0.83 |
| Fasting glucose (mg/dL) | 97.6 (12.3) | 118.8 (79.8) | 0.41 |
| Insulin, median (IQR) (μU/mL) | 16.1 (10.6-33.6) | 24.4 (15.4-34.0) | 0.69 |
| HOMA-IR, median (IQR) | 8.2 (7.9-12.7) | 4.6 (1.4-6.9) | 0.30 |
| APRI | 0.5 (0.4) | 0.4 (0.4) | 0.41 |
| FIB4 | 1.3 (0.7) | 1.1 (0.6) | 0.07 |
| CAP (dB/m) | 310.1 (32.5) | 321.3 (37.4) | 0.07 |
| LSM | |||
| ≥7.1 kPa | 13 (25.5%) | 32 (30.8%) | 0.50 |
| ≥8.6 kPa | 6 (11.8%) | 20 (19.2%) | 0.24 |
| ≥13.1 kPa | 1 (2%) | 8 (7.7%) | 0.27 |
| % HIV RNA <200 copies/mL | 48 (94.1%) | 100 (96.1%) | 0.69 |
| % HIV RNA <50 copies/mL | 45 (88.2%) | 93 (89.4%) | 0.82 |
| % HIV RNA <20 copies/mL | 9 (17.7%) | 15 (14.4%) | 0.60 |
| Current ART | 51 (100%) | 101 (97.1%) | 0.55 |
| Exposure to ART classes (current/prior use) | |||
| % PI | 8 (15.7%) | 29 (27.9%) | 0.09 |
| % NNRTI | 7 (13.7%) | 16 (15.4%) | 0.79 |
| % INSTI | 46 (90.2%) | 80 (76.9%) | 0.05 |
| % NRTI | 48 (94.1%) | 97 (93.3%) | 1.00 |
| % Entry inhibitors | 0 | 3 (2.9%) | 0.55 |